Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621517 · ClinicalTrials.gov registry record · Phase 2
Bupropion and Restless Legs Syndrome
A Phase 2 study of Restless Legs Syndrome, sponsored by East Tennessee State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00621517 is a Phase 2 study of Restless Legs Syndrome that has completed, run by East Tennessee State University. The registered enrollment target is 60 participants, below the 92-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00621517, a Phase 2 study of Restless Legs Syndrome, has completed, sponsored by East Tennessee State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bupropion
Study Locations (1)
Tennessee
- East Tennessee State University - Johnson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621517
The ClinicalTrials.gov registry entry for NCT00621517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (35% lower). The listed sponsor is East Tennessee State University, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00621517 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00621517 about?
NCT00621517 is a clinical study titled "Bupropion and Restless Legs Syndrome". The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).
What is the current status of trial NCT00621517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-02. Estimated completion is 2009-07.
What conditions does trial NCT00621517 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT00621517?
The interventions under investigation include: Placebo (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00621517?
This trial is sponsored by East Tennessee State University, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621517 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Simulated Driving Study in Restless Legs Syndrome
COMPLETED · Phase 2
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.